Ryan Evans , MD

Remote assessments in clinical trials

Anton Porsteinsson, MD

CITAD: Citalopram for the treatment of agitation in dementia—challenges of designing and executing intervention studies for behavioral disturbances in dementia

John Markham , MD

What to Do When Unintended Consequences are Painful: Lessons from Three Recent FDA Advisory Committees

**K-207**

Michel Berg , MD

Testing the equivalence of generic and innovator AEDs: are the FDA regulations sufficient?

David Oakes , PhD

The randomized start design in Parkinson's disease, can it really be used to infer disease modification?

John Treanor , MD

Study designs for Phase 1 studies of vaccines

Giovanni Schifitto , MD

A pilot study of creatine for treatment of fatigue in HIV infected individuals

Robert Griggs, MD

TBA

**Garvey Room 5-5220**

 

Ray Dorsey , MD and Bernard Ravina, MD

TBA

**Garvey Room 5-5220**

 

Karl Kieburtz, MD, MPH

NET-PD multiple outcomes, global test, what does it mean?

Steve Lamberti, MD

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): overview of a landmark study

David Foster, MD

The 5-year experience of a dyspareunia RCT: the Vulvar Vestibulitis Clinical Trial (VVCT)

Mark Mapstone, PhD

The Rochester Aging Study: community-based research in cognitive aging

Erika Augustine, MD and the Batten Study Team

Batten Disease Clinical Trials

Anthony Almudevar, PhD

A pathway modeling approach to gene discovery

David Shprecher, DO

A clinical and biomarker discovery initiative to identify individuals with premotor Parkinson's disease

Andrew McGarry , MD

A matter of SCAle: clinical trials in SCA 6

Sep 5, 2008

Adam Kelly , MD

Expanding the role of stimulant therapy in the post-stroke period

Fred Marshall , MD and Peter Como, PhD

Huntington Disease Meets the FDA, Part II: Aliens vs. Predators

Christopher Beck, PhD

Resampling approaches to statistical inference in clinical trials

Steve Lamberti , MD

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): overview of a landmark study

John Langfitt , PhD

Navigating NIH Peer Review: A Case Study of an RCT of Radiosurgery vs. Lobectomy for Epilepsy

Charles Duffy, MD, PhD

Late-Life Cognitive Decline: Measures and Mechanisms

Michael McDermott, PhD

Multiple outcome variables in clinical trials: an example from a planned trial in Duchenne muscular dystrophy

Ray Dorsey, MD, MBA

Randomized, controlled trial of an omega-3 fatty acid for Huntington disease

John Markman, MD

Lumbar Stenosis Outcomes Research (LUSTOR) trials I and II: a pair of double-blind, placebo-controlled crossover trials for the treatment of neurogenic intermittent claudication

Fred Marshall, MD and Peter Como, PhD

Huntington Disease meets the FDA

Michael Schlossmacher, MD

Lysosomal enzymes and alpha-synuclein steady-state

Kevin Biglan, MD, MPH and David Oakes, PhD

Dosage selection of isradipine for the treatment of Parkinson's Disease: a two-period design

Tiffani Voss, MD

The effects of sustained physiotherapy on fall reduction in Parkinson Disease

David Shprecher, DO

A peripheral leukocyte microarray investigation of tic remission in Tourette Syndrome

Lahar Mehta, MD

Heparin: a different point of view and possible application in Multiple Sclerosis

Brandy Fureman, PhD
NINDS Clinical Trial Group

NINDS Resources for Clinical Investigations

TBA

Anthony Almudevar, PhD and Roger Kurlan, MD

Some Issues in Adaptive Methodology

Giovanni Schifitto, MD

Valproic Acid for HIV-Associated Cognitive Impairment: An Enhanced Phase II Study

Roger Kurlan, MD

Identifying the best study design for pilot efficacy trials in Tourette’s Syndrome

Steven Frucht, MD
Associate Professor of Clinical Neurology
Columbia University Medical Center

Alcohol-responsive Movement Disorders - New Treatment Options

Bernard Ravina, MD, MSCE

Timing of Treatment Initiation in PD

Dan Skovronsky, MD, PhD
CEO, Avid Radiopharmaceuticals

Radiopharmaceuticals for Neurodegenerative Conditions

* * * Mt. Hope Professional Bldg, Windows Conference Room (next to Ste. 202) * * *

Alec B. O'Connor, MD

Desipramine vs. Pregabalin in Older Patients with Painful Diabetic Peripheral Neuropathy or Postherpetic Neuralgia

Ronnie Guillet, MD

Treatment of Infants After Resolution of Neonatal Seizures

Robert Dworkin, MD and Steve Schwid, MD

Proof-of-Concept Trial of Omega-3 and -6 Fatty Acid Supplementation in Multiple Sclerosis (or Clinically Isolated Syndromes?)

Peter Como, PhD

Quantitative Assessment of Caregiver Burden in PD

R. Michael Poole, MD, FACP

Practice Issues in the Implementation of Adaptive Clinical Trial Designs

Jeffrey L. Cummings, MD

Disease Modifying Therapies: How will we know if they are working?

John Markham, MD

Attenuation of Chronic Pain Following Lumbar Fusion:  Proposal for a Perioperative Analgesic Trial

Kevin Biglan, MD, MPH

Study in Presymptomatic Huntington’s Disease of Coenzyme Q10 Leading to Preventive Trials

Katia Noyes, PhD, MPH

Use of administrative data for examining patterns and costs of medical care: Application for Parkinson’s disease

Mark Mapstone, PhD

Practical Considerations for Cognitive Endpoints in Clinical Trials

Anthony Lang, MD

GDNF for Parkinson’s Disease: The Theory and the Evidence

Donna Palumbo, PhD

Clonidine in ADHD Treatment study (CAT) primary results

Richard A. Lewis, MD and Michael E. Shy, MD
Dept of Neurology, Wayne State University

High Dose Vitamin C Treatment of Charcot Marie Tooth Disease Type 1A

Giovanni Schifitto, MD

Identifying Relevant Biomarkers of Oxidative Stress in Subjects with HIV-Associated Cognitive Impairment

Kimberly P. Cockerham, MD
University of California, San Francisco

Thyroid Eye Disease Pilot Study and Beyond NORDIC TED 2005

**Mt. Hope Professional Bldg., Ste. 206**

William J. Groh, MD, MPH

Cardiac Involvement in Myotonic Dystrophy Type 1

Stanley Fahn, MD
Columbia University Medical Center

Study Designs For Neuroprotective Trials in PD

Aileen Shinaman, JD

COHORT: Initial Steps in Planning a Longitudinal, Observational Study of Members of the HD Community

**Biostats Conference Room MRBX G-11213**

Thomas Pearson, MD, MPH, PhD

Aggressive Lipid Management: Why, What, When, and in Whom?

Robert Dworkin, PhD and Michael McDermott, PhD

COMBination Antineuralgic Treatment in Peripheral Neuropathic Pain

Rabi Tawil, MD and Michael McDermott, PhD

Investigation of Corticosteroid Regimens for Treatment of Duchenne Muscular Dystrophy

Jonathan W. Mink, MD, PhD

Quantitative Assessment of Chorea and Dystonia

Kathy Hoeger, MD

Clinical Trials in the Long-term Management of Polycystic Ovary Syndrome (PCOS)